Son Colin, Tavakoli Samon, Bartanusz Viktor
Department of Neurosurgery, University of Texas Health Science Center, 7703 Floyd Curl Drive, MC 7843, San Antonio, TX 78229, USA.
School of Medicine, University of Texas Health Science Center, San Antonio, TX, USA.
J Clin Neurosci. 2016 Mar;25:58-61. doi: 10.1016/j.jocn.2015.05.055. Epub 2015 Nov 3.
Industry sponsorship of clinical research of degenerative diseases of the spine has been associated with excessive positive published results as compared to research carried out without industry funding. We sought the rates of publication of clinical trials of degenerative diseases of the spine based on funding source as a possible explanation for this phenomenon. We reviewed all clinical trials registered at clinicaltrials.gov relating to degenerative diseases of the spine as categorized under six medical subject heading terms (spinal stenosis, spondylolisthesis, spondylolysis, spondylosis, failed back surgery syndrome, intervertebral disc degeneration) and with statuses of completed or terminated. These collected studies were categorized as having, or not having, industry funding. Published results for these studies were then sought within the clinicaltrials.gov database itself, PubMed and Google Scholar. One hundred sixty-one clinical trials met these criteria. One hundred nineteen of these trials had industry funding and 42 did not. Of those with industry funding, 45 (37.8%) had identifiable results. Of those without industry funding, 17 (40.5%) had identifiable results. There was no difference in the rates of publication of results from clinical trials of degenerative diseases of the spine no matter the funding source.
与无行业资助的研究相比,脊柱退行性疾病临床研究的行业资助与已发表的过度阳性结果相关。我们探寻基于资金来源的脊柱退行性疾病临床试验的发表率,作为对此现象的一种可能解释。我们审查了clinicaltrials.gov上所有注册的与脊柱退行性疾病相关的临床试验,这些试验按照六个医学主题词分类(椎管狭窄、腰椎滑脱、椎弓峡部裂、脊椎关节强硬、腰椎手术失败综合征、椎间盘退变),且状态为已完成或已终止。这些收集到的研究被分类为有或没有行业资助。然后在clinicaltrials.gov数据库本身、PubMed和谷歌学术中查找这些研究的已发表结果。161项临床试验符合这些标准。其中119项试验有行业资助,42项没有。在有行业资助的试验中,45项(37.8%)有可识别的结果。在没有行业资助的试验中,17项(40.5%)有可识别的结果。无论资金来源如何,脊柱退行性疾病临床试验结果的发表率没有差异。